FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
East Hanover, N.J., Oct. 1, 2019– Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Diovan | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Failure | Pediatrics